[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2003299791A1 - Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity - Google Patents

Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity

Info

Publication number
AU2003299791A1
AU2003299791A1 AU2003299791A AU2003299791A AU2003299791A1 AU 2003299791 A1 AU2003299791 A1 AU 2003299791A1 AU 2003299791 A AU2003299791 A AU 2003299791A AU 2003299791 A AU2003299791 A AU 2003299791A AU 2003299791 A1 AU2003299791 A1 AU 2003299791A1
Authority
AU
Australia
Prior art keywords
imidazol
obesity
dihydro
ones
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299791A
Inventor
Jianqing Chen
Yuanwei Chen
David Gunn
Laszlo Matyas Hunyadi
Reina Natero
Jason Newcom
Stephen James O'Connor
Lin Yi
Hai-Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of AU2003299791A1 publication Critical patent/AU2003299791A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003299791A 2002-12-20 2003-12-19 Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity Abandoned AU2003299791A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43542902P 2002-12-20 2002-12-20
US60/435,429 2002-12-20
PCT/US2003/040843 WO2004058727A1 (en) 2002-12-20 2003-12-19 Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity

Publications (1)

Publication Number Publication Date
AU2003299791A1 true AU2003299791A1 (en) 2004-07-22

Family

ID=32682241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299791A Abandoned AU2003299791A1 (en) 2002-12-20 2003-12-19 Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity

Country Status (2)

Country Link
AU (1) AU2003299791A1 (en)
WO (1) WO2004058727A1 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105544B2 (en) 2001-07-05 2006-09-12 Synaptic Pharmaceutical Corporation Substituted alkyl amido piperidines
CA2512899A1 (en) 2003-01-14 2004-08-05 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP1622878A4 (en) * 2003-05-15 2008-04-09 Cytokinetics Inc Compounds, compositions and methods
AR045697A1 (en) 2003-07-14 2005-11-09 Arena Pharm Inc ARIL AND HETEROARIL FUSIONATED DERIVATIVES AS MODULATORS OF METABOLISM AND THE PREVENTION AND TREATMENT OF DISORDERS RELATED TO THE SAME
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2563164A1 (en) 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
MXPA06014793A (en) 2004-06-16 2007-02-16 Wyeth Corp Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase.
BRPI0512535A (en) 2004-06-24 2008-03-25 Incyte Corp unsubstituted piperidine compounds, their compositions and methods of modulation
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2580787A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP2266569A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084211A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives and their use as therapeutic agents
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JP2008526966A (en) 2005-01-14 2008-07-24 ワイス Amino-imidazolones for the inhibition of β-secretase
CN101111489A (en) 2005-02-01 2008-01-23 惠氏公司 Amino-pyridines as inhibitors of beta-secretase
DE102005025801A1 (en) * 2005-06-02 2006-12-07 Merck Patent Gmbh Use of chromone derivatives
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
PE20070461A1 (en) * 2005-09-26 2007-05-10 Wyeth Corp AMINO-5- [4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS B-SECRETASE INHIBITORS
US8193207B2 (en) 2005-12-05 2012-06-05 Incyte Corporation Lactam compounds and methods of using the same
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
GB2435828A (en) * 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Use of substituted phenyl-piperazine compounds for treatment of food related disorders
GB2435829A (en) * 2006-03-09 2007-09-12 Del Dr Esteve S A Spain Lab Pyrimidinyl-2-piperazine compounds for use in disorders related to food intake
MX2009001043A (en) 2006-08-08 2009-02-06 Sanofi Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use.
US7700606B2 (en) 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
PE20081559A1 (en) 2007-01-12 2008-11-20 Merck & Co Inc SPIROCHROMANONE DERIVATIVES SUBSTITUTED AS ACETYL COA CARBOXYLASE INHIBITORS
US8138197B2 (en) 2007-01-12 2012-03-20 Msd K.K. Spirochromanon derivatives
CL2008000791A1 (en) 2007-03-23 2008-05-30 Wyeth Corp COMPOUNDS DERIVED FROM 2-AMINO-5- (4-DIFLUOROMETOXI-FENIL) -5-FENIL-IMIDAZOLIDIN-4-ONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH EXCESSIVE BACE ACTIVITY, SUCH AS ILLNESS
CL2008001839A1 (en) 2007-06-21 2009-01-16 Incyte Holdings Corp Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases.
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
AR068875A1 (en) * 2007-10-16 2009-12-09 Novartis Ag DERIVATIVES OF 4-5-DIHIDRO-5-OXO-IMIDAZOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESS OF PREPARATION AND USE OF THE SAME AS INHIBITORS OF NPY AND 2 NON-PEPTIDIC RECEPTORS, FOR THE TREATMENT OF METHODOLOSTIC ANXIETRICS, DEPRESSIONS AND ENDOCRINS.
AR072707A1 (en) 2008-07-09 2010-09-15 Sanofi Aventis HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
BR112013008100A2 (en) 2010-09-22 2016-08-09 Arena Pharm Inc "gpr19 receptor modulators and the treatment of disorders related thereto."
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
EP2892892B1 (en) * 2012-09-07 2017-05-31 Janssen Pharmaceutica NV Imidazolin-5-one derivatives useful as fatty acid synthase (fasn) inhibitors for the treatment of cancer
JPWO2015037716A1 (en) 2013-09-12 2017-03-02 住友化学株式会社 Nitrogen-containing saturated heterocyclic compounds
WO2015095011A1 (en) * 2013-12-17 2015-06-25 Janssen Pharmaceutica Nv Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
CN104177298B (en) * 2014-09-18 2018-10-02 湘潭大学 Bis- substitution -4,5- dihydros -1H of 4,4--imidazoles -5- ketone, derivative and its synthetic method
AR103297A1 (en) 2014-12-30 2017-05-03 Forma Therapeutics Inc PIRROLO AND PIRAZOLOPIRIMIDINAS AS INHIBITORS OF THE SPECIFIC PROTEASE 7 OF UBIQUITINA
MA41291A (en) 2014-12-30 2017-11-07 Forma Therapeutics Inc PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER
CN116850181A (en) 2015-01-06 2023-10-10 艾尼纳制药公司 Treatment and S1P 1 Methods of receptor-related disorders
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
JP2018504432A (en) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド Isothiazolopyrimidinone, pyrazolopyrimidinone and pyrrolopyrimidinone as ubiquitin-specific protease 7 inhibitors
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN108349891B (en) 2015-06-22 2022-04-05 艾尼纳制药公司 Crystalline L-arginine salt of a compound for use in S1P1 receptor-related disorders
WO2017049321A1 (en) 2015-09-17 2017-03-23 Miller Marvin J Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
CN105272919B (en) * 2015-11-12 2018-01-05 中国科学院过程工程研究所 A kind of method that allantoin is prepared in the oligosaccharide syrup from saline cistanche
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
CN118146138B (en) * 2024-02-05 2024-11-05 广州安岩仁医药科技有限公司 Preparation method and application of 2-isopropoxy-5-methyl-4- (piperidin-4-yl) aniline hydrochloride

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022108A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
ATE212635T1 (en) * 1997-12-05 2002-02-15 1,3,8-TRIAZASPIRO(4,5)DECAN-4-ON DERIVATIVES
UY27450A1 (en) * 2001-09-24 2003-04-30 Bayer Corp PREPARATION AND USE OF IMIDAZOL DERIVATIVES FOR THE TREATMENT OF OBESITY
DE60208815T2 (en) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven PHENYL SUBSTITUTES 5-LOW NITROGEN-CONTAINING HETEROCYCLES FOR THE TREATMENT OF FAT ADJUSTMENT

Also Published As

Publication number Publication date
WO2004058727A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
EP2295053B8 (en) Novel 2H-chromen-2-one-3-carboxamides for medical uses
AU2935200A (en) Compounds for the treatment of obesity
HK1068335A1 (en) Novel arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003265589A1 (en) Process for the preparation of 1,1,1,2,2-pentafluoroethane
AU2003299648A1 (en) Substituted 4-phenyl-(1,3)-dioxanes
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AU2003224002A1 (en) Drugs for the arthritis treatment
AU2002236781A1 (en) Treatment for snoring
AU2003233820A1 (en) Method for the treatment of starch
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003269949A1 (en) Substituted 1,4-pyrazine derivatives
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003237460A1 (en) Combination treatments for purinoceptor-related disorders
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2003281158A1 (en) The treatment of emesis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase